Dashboard
Manage Tickers

XENTIntersect ENT, Inc.

Nasdaq www.intersectent.com


$ 28.25 $ 0.00 (0 %)    

Thursday, 12-May-2022 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 453.96 $ 0.49 (0.11 %)
DIA $ 400.38 $ 0.73 (0.18 %)
SPY $ 530.72 $ 0.80 (0.15 %)
TLT $ 92.13 $ -0.26 (-0.28 %)
GLD $ 220.44 $ -0.45 (-0.2 %)
$ 28.24
$ 28.23 x 1,591
$ 28.26 x 1,500
-- - --
$ 15.92 - $ 28.25
837,170
na
952.68M
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-04-2022 03-31-2022 10-Q
2 03-08-2022 12-31-2021 10-K
3 11-02-2021 09-30-2021 10-Q
4 08-06-2021 06-30-2021 10-Q
5 05-10-2021 03-31-2021 10-Q
6 03-09-2021 12-31-2020 10-K
7 11-02-2020 09-30-2020 10-Q
8 08-05-2020 06-30-2020 10-Q
9 05-11-2020 03-31-2020 10-Q
10 02-27-2020 12-31-2019 10-K
11 11-05-2019 09-30-2019 10-Q
12 08-05-2019 06-30-2019 10-Q
13 05-07-2019 03-31-2019 10-Q
14 02-28-2019 12-31-2018 10-K
15 11-05-2018 09-30-2018 10-Q
16 08-03-2018 06-30-2018 10-Q
17 05-03-2018 03-31-2018 10-Q
18 02-28-2018 12-31-2017 10-K
19 11-06-2017 09-30-2017 10-Q
20 08-04-2017 06-30-2017 10-Q
21 05-05-2017 03-31-2017 10-Q
22 02-28-2017 12-31-2016 10-K
23 11-03-2016 09-30-2016 10-Q
24 08-08-2016 06-30-2016 10-Q
25 05-09-2016 03-31-2016 10-Q
26 02-25-2016 12-31-2015 10-K
27 11-12-2015 09-30-2015 10-Q
28 08-10-2015 06-30-2015 10-Q
29 05-11-2015 03-31-2015 10-Q
30 03-11-2015 12-31-2014 10-K
31 11-10-2014 09-30-2014 10-Q
32 09-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

intersect-ent-q3-eps-048-down-from-034-yoy-sales-2440m-up-from-2272m-yoy
Intersect ENT Q3 EPS $(0.48) Down From $(0...
11/02/2021 20:47:08

Intersect ENT (NASDAQ:XENT) reported quarterly losses of $(0.48) per share. This is a 41.18 percent decrease over losses of $(0...

intersect-ent-announces-first-implants-of-propel-contour-in-patients-with-chronic-rhinosinusitis-following-frontal-sinus-surgery-in-europe
Intersect ENT Announces First Implants Of ...
10/28/2021 11:37:05

Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming p...

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
08/12/2021 14:04:35

 

svb-leerink-downgrades-intersect-ent-to-market-perform-announces-2825-price-target
SVB Leerink Downgrades Intersect ENT to Ma...
08/12/2021 08:51:11

SVB Leerink analyst Richard Newitter downgrades Intersect ENT (NASDAQ:XENT) from Outperform to Market Perform and announces ...

the-daily-biotech-pulse-fda-rejects-fibrogens-anemia-drug-crinetics-gains-on-positive-readout-biocryst-withdraws-public-offering
The Daily Biotech Pulse: FDA Rejects Fibro...
08/11/2021 12:14:37

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitti...

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
08/10/2021 14:32:07

 

the-daily-biotech-pulse-arcturus-soars-on-covid-19-vaccine-updates-mercks-keytruda-on-track-for-more-label-expansions-eliem-debuts
The Daily Biotech Pulse: Arcturus Soars On...
08/10/2021 11:55:36

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitti...

btig-downgrades-intersect-ent-to-neutral
BTIG Downgrades Intersect ENT to Neutral
08/10/2021 09:10:26

BTIG analyst Ryan Zimmerman downgrades Intersect ENT (NASDAQ:XENT) from Buy to Neutral.

canaccord-genuity-downgrades-intersect-ent-to-hold-lowers-price-target-to-2825
Canaccord Genuity Downgrades Intersect ENT...
08/09/2021 14:24:08

Canaccord Genuity analyst Kyle Rose downgrades Intersect ENT (NASDAQ:XENT) from Buy to Hold and lowers the price target from...

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
08/09/2021 14:24:00

Upgrades

guggenheim-downgrades-intersect-ent-to-neutral-announces-2825-price-target
Guggenheim Downgrades Intersect ENT to Neu...
08/09/2021 12:09:38

Guggenheim analyst Christopher Pasquale downgrades Intersect ENT (NASDAQ:XENT) from Buy to Neutral and announces $28.25 pric...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
08/06/2021 16:36:00

 

Core News & Articles
Stocks That Hit 52-Week Highs On Friday
08/06/2021 14:03:21

    Before 10 a.m. ET on Friday, 175 companies set new 52-week highs.

medtronic-expands-its-ent-portfolio-with-intersect-ent-acquisition-for-2825share
Medtronic Expands Its ENT Portfolio With I...
08/06/2021 12:19:30

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
08/06/2021 12:07:36

 

intersect-ent-q2-earnings-insights
Intersect ENT: Q2 Earnings Insights
08/06/2021 11:52:34

  Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q2 results. Quarterly Results Earning...

intersect-ent-shares-resume-trade-up-12
Intersect ENT Shares Resume Trade, Up 12%
08/06/2021 11:36:04

intersect-ent-q2-adj-eps-049-misses-043-estimate-sales-2730m-miss-2802m-estimate
Intersect ENT Q2 Adj. EPS $(0.49) Misses $...
08/06/2021 11:22:28

Intersect ENT (NASDAQ:XENT) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.4...

Core News & Articles
Medtronic To Buy Intersect ENT For $28.25/...
08/06/2021 11:01:31

earnings-scheduled-for-august-6-2021
Earnings Scheduled For August 6, 2021
08/06/2021 08:22:44

  Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 pe...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION